GRML vs INIS vs VTRS Stock Comparison

Greenland Mines, Radnostix and Viatris Prices as of Oct 26, 2026 Peers: Industry group
GRML Greenland Mines Ltd
$5.79 -60.5% 1M +929.2% 1Y
Market cap
$14.06M
P/E
–
Revenue (TTM)
—
Div. yield
–
Generic Drugs Healthcare
1 win
INIS Radnostix Inc
$0.05 -16.7% 1M 0.0% 1Y
Market cap
$21.16M
P/E
–
Revenue (TTM)
$11.23M
Div. yield
–
Generic Drugs Healthcare
1 win
VTRS Viatris Inc
$18.29 +2.6% 1M +76.7% 1Y
Market cap
$21.85B
P/E
–
Revenue (TTM)
$14.74B
Div. yield
–
Generic Drugs Healthcare
6 wins

Head to Head

8 decided of 12

Viatris leads on 6 of the 12 questions below (Viatris 6, Radnostix 1, Greenland Mines 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionGRMLINISVTRSLeader
Larger companyMarket capitalisation $14.06M $21.16M $21.85B VTRS
Cheaper on earningsLower P/E, profitable companies only -0.6x -7.4x -53.2x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS — — 7.0x –
Faster revenue growthRevenue growth, trailing twelve months — -23.7% +4.4% VTRS
More profitableNet margin, trailing twelve months — -25.5% -2.8% VTRS
Better return on capitalReturn on invested capital — — -0.2% –
Less leveragedLower net debt / EBITDA — -0.5x 4.6x INIS
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +929.2% 0.0% +76.7% GRML
Better 5-year returnAnnualised price return, 5 years — -13.0%/yr +6.9%/yr VTRS
Less volatileAnnualised volatility, 1 year 445.7% 169.2% 32.4% VTRS
Higher overall scoreMean of the five percentile scores vs peers 34/100 51/100 66/100 VTRS

Percentile Scorecard

GRMLINISVTRS

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisGRMLINISVTRS
Valuation 13 #542 of 626 83 #110 of 626 93 #42 of 626
Growth 2 #590 of 604 2 #591 of 604 47 #318 of 604
Profitability 68 #179 of 555 72 #159 of 555 81 #106 of 555
Financial Health 78 #147 of 658 16 #553 of 658 23 #510 of 658
Shareholder Returns 7 #342 of 368 84 #61 of 368 87 #49 of 368
Overall 34 51 66
  • GRML ranked among 673 companies in Pharmaceuticals and Biotechnology
  • INIS ranked among 673 companies in Pharmaceuticals and Biotechnology
  • VTRS ranked among 673 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodGRMLINISVTRSSPY
1 month -60.5%-16.7%+2.6% -0.8%
3 months +2,947.4%-28.6%+3.7% +3.5%
6 months +1,129.8%-37.5%+23.5% +7.0%
Year to date +1,903.5%-16.7%+46.9% +12.2%
1 year +929.2%0.0%+76.7% +13.0%
3 years -45.8%0.0%+108.6% +86.3%
3 years, per year -18.5%0.0%+27.8% +23.1%
5 years —-50.0%+39.6% +68.6%
5 years, per year —-13.0%+6.9% +11.0%
10 years —-37.5%-52.0% +258.0%
10 years, per year —-4.6%-7.1% +13.6%

Risk

MeasureGRMLINISVTRSSPY
Volatility, 1Y 445.7%169.2%32.4% 12.7%
Downside volatility, 1Y 158.9%264.0%29.6% 12.7%
Beta vs S&P 500, 1Y 2.772.050.70 1.00
Return / volatility, 1Y 2.080.002.37 1.02
Max drawdown, 5Y -99.0%-70.0%-52.9% -25.4%
From 52-week high -61.1%-54.5%-2.0% -1.8%
52-week high $14.89$0.11$18.66 $779.14
52-week low $0.17$0.04$10.11 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleGRMLINISVTRS
P/E now vs peer median -0.7xmedian 17.1x -9.2xmedian 17.1x -51.8xmedian 17.1x
P/S now vs peer median —median 8.8x 2.4xmedian 8.8x 1.4xmedian 8.8x
EV/EBITDA now vs peer median —median 17.1x -11.0xmedian 17.1x 12.3xmedian 17.1x
P/FCF now vs peer median -1.0xmedian 18.0x -28.6xmedian 18.0x 10.7xmedian 18.0x
P/B now vs peer median 0.3xmedian 2.1x 14.0xmedian 2.1x 1.5xmedian 2.1x
PEG now vs peer median 0.01median 0.31 0.25median 0.31 1.69median 0.31

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsGRMLINISVTRS
Revenue – $11.23M $14.74B
Gross profit – $6.04M $5.13B
Operating income -$18.67M -$2.90M -$87.30M
Net income -$21.77M -$2.86M -$410.70M
Free cash flow -$14.22M -$925.24K $1.95B
R&D $1.28M $490.38K $1.02B
EPS (diluted) $-8.60 $-0.01 $-0.35
Cash & equivalents $9.34M $1.20M $886.50M
Total debt $2.07M $8.26M $13.35B
Shares (diluted) 2.53M 529.12M 1.16B
Enterprise value -$19.81M $15.27M $16.86B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricGRMLINISVTRS
P/E -0.7x -9.2x -51.8x
P/FCF -1.0x -28.6x 10.7x
P/Operating cash flow -1.0x -70.3x 9.0x
P/S – 2.4x 1.4x
P/B 0.3x 14.0x 1.5x
P/Tangible book 1.6x -21.4x 36.0x
EV/EBITDA – -11.0x 12.3x
EV/EBIT -0.3x -9.5x -383.4x
EV/Revenue – 2.5x 2.3x
EV/FCF -0.4x -29.8x 17.1x
EV/Operating cash flow -0.4x -73.3x 14.4x
PEG (3Y EPS CAGR) 0.01 0.25 1.69

Growth

14 metrics
MetricGRMLINISVTRS
Revenue growth (1Y) – -23.7% 4.4%
Revenue CAGR (3Y) – -2.6% -1.9%
Gross profit growth (1Y) – -32.4% -0.7%
Gross profit CAGR (3Y) – -4.0% -6.0%
Operating income growth (1Y) -127.6% -1,245% 96.6%
Operating income CAGR (3Y) -166.2% -50.5% -27.6%
Net income growth (1Y) -91.7% -2,437% 88.2%
Net income CAGR (3Y) -125.4% -38.0% -30.5%
EPS growth (1Y) 48.6% -2,429% 88.1%
EPS CAGR (3Y) -48.2% -37.0% -30.6%
Operating cash flow growth (1Y) -158.2% -157.0% 12.9%
Operating cash flow CAGR (3Y) -236.9% -41.4% -3.0%
Free cash flow growth (1Y) -158.2% -2,469% 11.6%
Free cash flow CAGR (3Y) -236.9% -69.5% -3.6%

Profitability

14 metrics
MetricGRMLINISVTRS
Gross margin – 53.8% 34.8%
EBITDA margin – -22.3% 18.4%
Operating margin – -25.8% -0.6%
Pretax margin – -28.3% -4.5%
Net margin – -25.5% -2.8%
FCF margin – -8.2% 13.3%
Operating cash flow margin – -3.4% 15.8%
Return on equity -39.8% -140.0% -2.8%
Return on assets -34.9% -18.8% -1.1%
Return on invested capital – – -0.2%
Return on capital employed -30.5% -22.8% -0.3%
Asset turnover – 0.7x 0.4x
Cash conversion (OCF / net income) 0.7x 0.1x -5.7x
Stock comp / revenue – 3.7% 1.2%

Financial Health

11 metrics
MetricGRMLINISVTRS
Debt / assets 0.5% 14.0% 38.1%
Debt / equity 0.0x 1.2x 0.9x
Net debt / EBITDA – -0.5x 4.6x
Debt / FCF 0.0x -2.5x 6.8x
Liabilities / assets 10.9% 88.6% 59.3%
Equity / assets 89.1% 11.4% 40.7%
Interest coverage -2,872x -8.5x -0.2x
Current ratio 10.1x 0.8x 1.6x
Quick ratio 7.7x 0.6x 0.7x
Cash ratio 7.7x 0.3x 0.1x
Altman Z-score – -9.85 1.13

Shareholder Returns

7 metrics
MetricGRMLINISVTRS
Dividend yield – – 2.6%
Net buyback yield -49.5% -0.1% 1.4%
Shareholder yield -49.5% -0.1% 4.1%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusGRMLINISVTRS
Forward P/E – – 7.0xFY2026
EPS, next fiscal year – – $2.62FY2026
EPS growth, next FY – – +11.5%FY2026
EPS growth, the year after – – -1.5%
Revenue, next fiscal year – – $15.31BFY2026
Revenue growth, next FY – – +7.0%FY2026
Revenue growth, the year after – – -4.8%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersGRMLINISVTRS
Held by institutions 12.0% – 89.9%
Institutions holding 47 – 1,028
Change in shares held, QoQ +96.3% – +5.6%
Institutions buying 34 – 486
Institutions selling 2 – 318
Buyers to sellers 17.00 – 1.53

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

GRMLINISVTRS
GRML 1.00 -0.05 0.08
INIS -0.05 1.00 0.04
VTRS 0.08 0.04 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, GRML, INIS and VTRS?

Viatris (VTRS) is the largest by market capitalisation: Greenland Mines (GRML) $14.06M, Radnostix (INIS) $21.16M, Viatris (VTRS) $21.85B.

Which company is growing faster?

Viatris (VTRS) grew revenue fastest over the trailing twelve months: Radnostix (INIS) -23.7%, Viatris (VTRS) +4.4%.

Which company is more profitable?

Viatris (VTRS) has the highest net margin (Radnostix (INIS) -25.5%, Viatris (VTRS) -2.8%).

Which stock has performed better?

Over the past year Greenland Mines (GRML) returned the most: Greenland Mines (GRML) +929.2%, Radnostix (INIS) 0.0%, Viatris (VTRS) +76.7%. Over five years, Viatris (VTRS) compounded fastest (Radnostix (INIS) -13.0%/yr, Viatris (VTRS) +6.9%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Viatris (VTRS) has been the steadiest (Greenland Mines (GRML) 445.7%, Radnostix (INIS) 169.2%, Viatris (VTRS) 32.4%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, GRML, INIS and VTRS?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Viatris (VTRS) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.